Compare General Mills, Inc. (GIS) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Medpace Holdings Inc — how do they compare? General Mills, Inc. trades at $38.71 (market cap $19.46B), while Medpace Holdings Inc trades at $534.08 (market cap $15.11B). The key difference: General Mills, Inc. is the larger of the two by market cap, and General Mills, Inc. pays a 6.69% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| GIS | MEDP | |
|---|---|---|
Market Cap | $19.46B | $15.11B |
Sector | Consumer Staples | Technology |
52-Week High | $51.27 | $620.59 |
52-Week Low | $32.17 | $308.88 |
Enterprise Value | $32.95B | $14.58B |
Dividend Yield | 6.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $36.46, down 0.38% on the day, with a neutral technical signal and mixed earnings history. The stock shows a low P/E of 9.23 and pays a dividend, but faces net income margin pressure at -0.48% for 2026. Recent news highlights partnerships in regenerative agriculture and cost-saving initiatives targeting $3 billion by 2030 to combat soft consumer demand.
Outlook remains cautious with sales pressure expected in 2027, though valuation appears attractive. Key risks include competitive pressures and margin recovery challenges. Analyst consensus is mixed with a hold-heavy rating, suggesting patience for turnaround execution amid economic headwinds.
Medpace (MEDP) trades at $534.85, down 0.25% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. The company shows strong profitability with a 17.19% net income margin and 77.25% ROE, though valuations are elevated with a P/E of 33.31. Recent earnings have consistently beaten estimates, and cash flow is projected to improve in 2026. News highlights focus on CRO demand shifts and a class action lawsuit from June 2026.
Outlook remains mixed; strong earnings momentum and operational efficiency support upside, but high valuation and legal overhangs pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term appreciation potential amid balanced investor sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
